Ewing's sarcoma is the second most common human bone tumor in childhood. Here, we investigated the sensitivity of the Ewing tumor cell line, SK-N-MC, to the apoptotic effect of type I (IFNa) and type II (IFNc) interferons and TNFa. We demonstrate that although IFNa and TNFa alone are unable to induce cell death, they act in synergy with IFNc to induce SK-N-MC cell apoptosis. The synergistic induction of apoptosis correlated with the synergistic induction of TNFa-related apoptosis-inducing ligand (TRAIL) mRNA and TRAIL protein synthesis as well as of TRAIL secretion. Preparations of inducer-free supernatants from SK-N-MC cells stimulated with combinations of cytokines were shown to be cytotoxic for untreated SK-N-MC cells. This cytotoxicity was partially inhibited by addition of TRAILR2/Fc fusion protein, indicating that the secreted TRAIL mediates, at least in part, the apoptotic effect displayed by the supernatants of stimulated SK-N-MC cells. We have shown that the presence of IFNc is required to allow the sustained expression of IRF1 in SK-N-MC cells stimulated by addition of IFNa or TNFa suggesting that IRF1 plays a role in the synergistic induction of apoptosis by combinations of cytokines. Furthermore, we have shown that inhibition of NF-jB activation contributes to the IFNc-mediated sensitization to the apoptotic effect of TNFa. To our knowledge, this is the first report showing that interferon/cytokine combinations are able to induce TRAIL gene expression and TRAIL protein synthesis and secretion in Ewing sarcoma-derived cells. We believe that the observations reported here might contribute to the development of alternative new approaches to the treatment of Ewing tumors resistant to conventional therapy.
Introduction
Ewing's sarcoma is the second most common human bone tumor that predominantly affects children and young adults (Horowitz et al., 1997) . In 85% of patients, the karyotype shows an equilibrated translocation between chromosomes 11 and 22 (Aurias et al., 1983; Delattre et al., 1992) generating the fusion protein EWS/ FLI1 between the 5 0 end of the EWS gene and the 3 0 end of the FLI 1 gene. The EWS/FLI1 protein was shown to be responsible for tumorigenesis (May et al., 1993; Kovar et al., 1996; De Alava and Gerald, 2000; Arvand and Denny, 2001) . Therapy includes essentially surgery and/or chemotherapy and radiotherapy (RodriguezGalindo et al., 2003) . Resistance to current treatment protocols remains a major concern in Ewing's sarcoma since, despite these aggressive therapies, survival is poor in metastatic patients and new therapeutic approaches or new anticancer agents are urgently required (Fizazi et al., 1998; Pinkerton et al., 2001; Shankar et al., 2003) .
Previous studies have shown that interferons (IFNs) and tumor necrosis factor a (TNFa) are able to inhibit the growth of Ewing tumor cells in vitro (Van Valen et al., 1993; Sance´au et al., 2000) . Recently, IFNa and IFNb have been shown to impair Ewing xenograft take in nude mice and to inhibit the development of already established tumors (Sance´au et al., 2002) .
IFNs belong to a family of cytokines that display a wide range of biological effects such as antiviral, antiproliferative, immunomodulatory and antitumor activities (Stark et al., 1998) . IFNs are also negative regulators of angiogenesis (Singh et al., 1995) and a possible role of apoptosis in mediating the antitumor effects of IFNs has been postulated (Chawla-Sarkar et al., 2003) . IFNs alone or combined with other antitumor drugs are now used in cancer therapies and new applications are under investigation (Wadler and Schwartz, 1997; Borden, 1998; Pfeffer et al., 1998; Borden et al., 2000) Although IFNa (type I) and IFNg (type II) shared common biological properties, signal transduction of IFNg and IFNa involves both similar and dissimilar pathways. Synergistic biological effects between IFNg and IFNa have been reported (Darnell et al., 1994; Stark et al., 1998) . The therapeutic potential of type I and type II IFNs, as well as their associations with other cytokines, are currently under investigation in various types of cancer (Lienard et al., 1992; .
TNFa is a pleiotropic proinflammatory cytokine that kills various tumor cells in vitro and mediates antitumor effects in vivo (Tracey and Cerami, 1994; Lejeune, 2002) . In many cases, the antitumor effect of TNFa was synergistically increased by IFNg (Suk et al., 2001a) . However, as was shown recently, Ewing cell lines are resistant to apoptosis induced by TNFa due to the activation of the transcription factor NF-kB, which triggers several antiapoptotic signals in these cells (Javelaud et al., 2000; Javelaud and Besanc¸on, 2001) .
IFNs were found to induce expression of the proapoptotic protein TNFa-related apoptosis-inducing ligand (TRAIL) in monocytes and dendritic cells Griffith et al., 1999) . TRAIL is a type II transmembrane cytokine molecule of the TNF family and a potent inducer of apoptosis. TRAIL or TRAIL inducers may be a promising therapy for treatment of human cancer as recombinantly produced TRAIL induces apoptosis in a wide variety of transformed cell lines (Wiley et al., 1995; Pitti et al., 1996; Griffith et al., 1998; Walczak et al., 1999; Ashkenazi, 2002 ) including Ewing's sarcoma (Ashkenazi et al., 1999; Van Valen et al., 2000; Kontny et al., 2001; Kumar et al., 2001; Mitsiades et al., 2001) . However, Nesterov et al. reported that TRAIL triggers apoptosis in normal prostate epithelial cells and results of Ashkenazi's group have shown that some preparations of recombinant TRAIL are cytotoxic for normal hepatocytes (Lawrence et al., 2001; Nesterov et al., 2002) .
To contribute to the development of new pharmacological approaches to the treatment of Ewing sarcoma, we investigated the sensitivity of the Ewing tumor cell line SK-N-MC, to the apoptotic effect of several combinations of cytokines. As IFNg has been shown to increase the sensitivity of many cells to various apoptotic stimuli (Suk et al., 2001a; Chawla-Sarkar et al., 2003) , we investigated whether IFNg acts in synergy with either IFNa or TNFa to induce apoptosis of SK-N-MC cells. In the present work we demonstrate that although IFNa and TNFa alone are unable to induce cell death, they act in synergy with IFNg to induce SK-N-MC cell death. We show that the synergistic induction of apoptosis correlated with the synergistic induction of TRAIL mRNA and TRAIL protein synthesis as well as of TRAIL secretion. Our results are consistent with the notion that TRAIL contributes in an autocrine or paracrine manner to the triggering of Ewing cell SK-N-MC apoptosis induced by IFNg combined with IFNa or TNFa. Furthermore, we also show that inhibition of NF-kB activation contributes to the IFNg-mediated potentiation of the apoptotic effect of TNFa.
Results
IFNg either alone or combined with IFNa or TNFa induces apoptosis of the Ewing tumor cell SK-N-MC
We investigated the effect of IFNg treatment or IFNg/ IFNa, IFNg/TNFa combinations on apoptosis of the SK-N-MC cell line derived from a Ewing sarcoma. Apoptosis was assessed 24 h after the beginning of treatment by observation of several typical features: cellular toxicity, Apo2-7 labeling, determination of nucleosomal DNA fragmentation and evaluation of the percentage of apoptotic nuclei by Hoescht staining. Table 1 shows that treatment of cells with IFNg alone resulted in 17% of nonviable cells while no effect was observed when cells were treated with IFNa or TNFa alone even at higher concentrations than those indicated in Table 1 (not shown). However the percentage of apoptosis increased synergistically in IFNg/IFNa-and IFNg/TNFa-treated cells (42 and 67%, respectively), as compared to IFNg-treated cells. The Apo2-7 fluorescent staining was enhanced in cells stimulated with either IFNg or IFNg/IFNa combination (1.45-and 1.6-fold increase, respectively). A much higher increase in Apo2-7 expression was observed in cells stimulated with the combination of IFNg/TNFa (2.15-fold increase). Almost no modification of Apo2-7 expression was observed in cells stimulated with IFNa or TNFa alone. Apoptosis was further evaluated by a nucleosomal DNA fragmentation assay. As shown in Table 1 Kumar et al., 2001; Mitsiades et al., 2001) . Since IFNs were reported to induce TRAIL in other cell systems Griffith et al., 1999; Langaas et al., 2001; Oshima et al., 2001; Shin et al., 2001; Toomey et al., 2001) , we investigated whether TRAIL induction participated in IFNg-, IFNg/IFNa-or IFNg/TNFainduced SK-N-MC cell death. Figure 1a shows the kinetics of TRAIL mRNA induction, in response to stimulation with IFNg alone or in combination with IFNa or TNFa. TRAIL mRNA was undetectable in both control cells and cells stimulated with TNFa or IFNa alone. Treatment of cells with IFNg alone induced a weak and transient expression of TRAIL mRNA, which was detectable after treatment of 6-12 h but not after longer treatments. Addition of IFNa or TNFa to IFNg resulted in an increase in the level of TRAIL mRNA, which was already detectable after 6 h of stimulation, increased up to 24 h, decreased thereafter and became undetectable after 30 h of stimulation (not shown). We next investigated whether this increase also occurred at the protein level. Figure 1b shows the Western blot analysis of SK-N-MC cell lysates prepared after 30 h of treatment with the cytokines. PHA-stimulated Jurkat cell lysates (Martinez-Lorenzo et al., 1998) and retinoic acid-stimulated NB4 cell lysates (Altucci et al., 2001) were both used as positive controls. The use of a polyclonal antibody raised against recombinant TRAIL allowed the detection of a 26 kDa TRAIL protein in IFNg-treated SK-N-MC cells as well as in the Jurkat and NB4 stimulated cells used as positive controls. Addition of IFNa or TNFa to IFNg resulted in an increased expression of TRAIL protein, which is in good agreement with the enhanced expression of TRAIL mRNA that we observed under the same stimulation conditions.
Flow cytometry analysis using a monoclonal anti-TRAIL antibody confirmed that TRAIL protein was synergistically induced by treatment with IFNg/IFNa and IFNg/TNFa (Figure 2a ). TRAIL-R2 receptor (DR5) was also expressed in SK-N-MC cells and was enhanced in the costimulated cells (Figure 2b ). TRAIL-R2 receptor was also detectable by Western blot analysis (not shown).
Secretion of TRAIL by stimulated SK-N-MC cells
To examine whether TRAIL protein was secreted after treatment of SK-N-MC cells with cytokines, TRAIL concentration was determined both in the cell culture supernatants and in the cell lysates by using two specific ELISA tests that gave similar results. As shown in Table 2 , supernatants from stimulated cells contained from 0.6 to 0.7 ng of TRAIL for 10 6 cells after 30 h of stimulation with either IFNg/IFNa or IFNg/TNFa while supernatants from cells stimulated with IFNg alone contained 0.36 ng of TRAIL for 10 6 cells. The amount present in the latter supernatants was low in agreement with the weak and transient induction of TRAIL mRNA and the modest apoptotic effect that were observed in cells stimulated with IFNg. Low amounts of TRAIL (less than 0.3 ng/10 6 cells) were also spontaneously secreted by the unstimulated cells. Determination of the amount of TRAIL in the corresponding lysates showed that although most of the induced TRAIL was secreted, part of it remained cell associated ( Table 2 ). /ml) were stimulated with IFNg (1000 U/ml), IFNa (1000 U/ml), TNFa (1000 U/ml) or with a combination of either IFNg/IFNa or IFNg/TNFa in 2% FCS RPMI for 6, 12, 18 and 24 h. Total RNAs were reverse-transcripted and the cDNAs were amplified by PCR with specific primers for TRAIL. The Ewing-specific gene, EWS/FLI1, was used to normalize the PCR reaction. (b) Western blot analysis: lysates (200 mg protein) of cells, stimulated for 30 h as in (a) were analysed by Western blot using a polyclonal goat anti-TRAIL antibody. PHA-treated Jurkat and retinoic acid-treated NB4 cells were used as positive controls. Blotting with an anti-actin antibody was used to confirm the equal loading of the lanes Since the amount of TRAIL secreted by IFNgstimulated cells was low, the characterization of the secreted TRAIL was done in inducers-free supernatants that were prepared from cells stimulated with IFNg/IFNa and IFNg /TNFa. In order to investigate the cytotoxic properties of the secreted TRAIL, cells were stimulated for 6 h with IFNg combined with IFNa or TNFa, carefully washed, resuspended in fresh medium and then cultured for 2 additional days. As shown in Table 2 , the supernatants from control cells or cells stimulated IFNg/ IFNa or IFNg/TNFa contained, respectively, 0.075, 0.295 and 0.48 ng of TRAIL for 10 6 cells. The synergistic effect on TRAIL production was more pronounced when the inducers were withdrawn after a 6 h stimulation. This observation is probably related to the fact that this condition of stimulation led to a higher cell viability than when cytokines were left in the medium and this may influence the efficiency of TRAIL synthesis. The cytotoxicity of the inducer-free supernatants were then assayed on untreated SK-N-MC cells. As shown in Figure 3a , supernatants from stimulated cells exerted a concentration-dependent cytotoxicity. The profile of the concentration response curve obtained with these supernatants was similar to that obtained when the cells were treated with recombinant TRAIL (Figure 3b ). Supernatants from control cells displayed only a low cytotoxic effect in agreement with the presence of the lower amounts of TRAIL detected by ELISA.
In order to investigate whether TRAIL present in the supernatants played a role in their cytotoxic activity, we assessed the cytotoxicity of serial dilutions of inducerfree supernatants that had been preincubated or not with a TRAIL-R2 receptor/Fc chimera, which neutralizes recombinant TRAIL activity (Walczak et al., 1997; Kayagaki et al., 1999; Altucci et al., 2001) . As shown in Figure 3c , addition of TRAIL-R2/Fc chimera markedly reduced cell death triggered by the inducer-free supernatants indicating that TRAIL present in the supernatants contributed to the apoptotic effect observed. However, the fact that the cytotoxic activity was not et al., 2000) . In our cell model too, IRF1 induction correlated with induction of the active form of caspase-7 (Figure 4 ). Taken together, these findings suggest that the Stat1/ IRF1 pathway plays a role in the synergistic induction of cell death by the combination of IFNg and IFNa or IFNg and TNFa
Downregulation of TNFa-induced NF-kB activity by IFNg
There is now accumulating evidence that activation of the transcription factor NF-kB results in a resistance of cells to apoptotic stimuli (Baldwin, 2001 ). Inhibition of NF-kB activation results in an extensive sensitization of several cell lines to TNFa-induced apoptosis including Ewing sarcoma-derived cells (Javelaud et al., 2000; Javelaud and Besanc¸on, 2001) . As IFNg has been reported either to stimulate (Cheshire and Baldwin, 1997) or to reduce (Suk et al., 2001a ) NF-kB activation by TNFa, we investigated its effect on NF-kB activation in SK-N-MC cells.
The binding of the NF-kB subunit p65 to its specific target DNA sequence was measured by the Trans-AM p65 assay kit (Kretz-Remy et al., 2001). As shown in Figure 5a , treatment of cells with TNFa resulted in a strong stimulation of the binding of p65 to its target sequence and addition of IFNg to TNFa did not affect this binding. However, it has been reported that an inhibition of NF-kB activity can occur without any effect on the binding of this factor to its target DNA sequence (Suk et al., 2001a, b) . We therefore investigated the effect of IFNg treatment on TNFa-induced NF-kB transcriptional activity. This activity was measured by transfection of cells with the (Igk)3-conaluc plasmid, a luciferase reporter construct containing three kB sites of the Igk chain enhancer upstream of the minimal conalbumin promoter (Munoz et al., 1994) . Results are presented in Figure 5b . Treatment of the transfected 
SK-N-MC cells for 8 h with TNFa increased their
luciferase activity sixfold as compared to that measured in control cells. In contrast, although IFNg had no effect on NF-kB activity when added alone, it totally inhibited its activation by TNFa.
This result strongly suggests that the IFNg-mediated downregulation of NF-kB activity contributes to the synergistic induction of apoptosis by TNFa and IFNg. In contrast, this effect does not account for the synergistic apoptotic effect of IFNg and IFNa as, like IFNg, IFNa either alone or combined with IFNg had no effect on NF-kB activity (not shown).
Discussion
Here we report that IFNg (type II IFN) cooperates with IFNa (type I IFN) or TNFa to induce apoptosis of the Ewing cell line SK-N-MC. Interestingly, neither IFNa nor TNFa alone is able to induce apoptosis of these cells in the absence of IFNg. Thus, this means that IFNa and TNFa activate biochemical pathways that converge with those activated by IFNg. The fact that the presence of IFNg is required to trigger cell apoptosis suggests that biochemical signals induced by this cytokine play an indispensable role.
We have investigated the possibility that induction of cytotoxic mediators such as TRAIL could be involved in the cytokine-mediated effect. (Oshima et al., 2001) and soluble TRAIL was detected in sera of multiple sclerosis patients treated with IFNb (Wandinger et al., 2003) . Interestingly, we were able to show that preparations of inducer-free supernatants from SK-N-MC cells stimulated with combinations of cytokines (containing TRAIL protein) are cytotoxic for untreated SK-N-MC cells. This cytotoxicity was partially inhibited by addition of the soluble recombinant TRAIL-R2/Fc fusion protein, which blocks the interaction between TRAIL and its receptor (Walczak et al., 1997) . It may thus be concluded that the secreted TRAIL mediates, at least in part, the apoptotic effect displayed by the supernatants of cytokinesstimulated SK-N-MC cells. Our observation suggests that in addition to cell-associated TRAIL, which probably kills the producing cell, soluble TRAIL secreted by stimulated cells will trigger apoptosis of neighboring cells and that this scenario may be biologically relevant.
Induction of TRAIL by IFNg was reported in hepatoma (Shin et al., 2001) , melanoma (Griffith et al., 1998) Signaling pathways involved in IFNg-induced sensitization to apoptosis. Cells were stimulated for 1 or 24 h with either IFNa 1000 U/ml, IFNg 1000 U/ml, TNFa 1000 U/ml alone or combinations of IFNg/IFNa or IFNg/TNFa. After cell lysis, 50 mg of proteins were submitted to Western blot analysis with the following antibodies: anti-IRF1, anti-Stat1 p91 and anti-phospho-S727 and -Y701 Stat1 as well as anti-caspase-7. Anti-actin antibody was used for loading control
IFNc combined with IFNa or TNFa induce TRAIL in EWING cells
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In SK-N-MC cells, IFNg but not IFNa induced a very low and transient level of TRAIL mRNA. However, TRAIL gene expression was synergistically induced by costimulation with IFNg and IFNa. Although type I and type II IFNs share many biological properties, their synergistic effect on apoptosis may be explained by the fact that they recognize different cell surface receptors and that they trigger different (complementary) signaling pathways (Stark et al., 1998) . We have analysed the IFNg dependent intracellular signals, such as IRF1 induction, STAT1 phosphorylation and caspase-7 activation. The fact that the two combinations, TNFa/IFNg or IFNa/IFNg activated these signals with different efficiencies is probably linked to the fact that, although IFNg is common to both combination, the second signal is triggered by TNFa or IFNa, two cytokines that bind to different receptors. The efficiency of these receptors to activate pathways that converge on common effectors such as STAT1, IRF-1 or caspase-7 may vary. We have shown that the presence of IFNg is required to allow the sustained expression of IRF1 in SK-N-MC cells stimulated by addition of IFNa or TNFa. As an apoptotic effect of IRF1 in Ewing sarcoma-derived cells has been previously demonstrated by inducible ectopic expression of this factor in these cells (Sance´au et al., 2000) , these results suggest that sustained expression of IRF1 plays a role in the synergistic induction of apoptosis by combinations of cytokines in SK-N-MC cells. Our results are in line with recently reported data describing the involvement of IRF1 induction as a mediator of the synergistic induction of apoptosis after treatment of cervical cancer cells ME 180 with combinations of IFNg or IFNa with TNFa (Suk et al., 2001a, b) . However, in Ewing cells, IFNa cannot replace IFNg for sensitizing cells to TNFa-induced apoptosis.
It was recently shown that inhibition of NF-kB in Ewing sarcoma cells, as a consequence of the overexpression of a degradation-resistant form of IkBa sensitized these cells to TNFa-Àinduced apoptosis and resulted in a loss of their ability to generate tumors in nude mice (Javelaud et al., 2002) . In an attempt to understand the molecular mechanism underlying the synergistic cytotoxic effect of IFNg and TNFa, we therefore investigated the possible regulation of the transcription factor NF-kB by IFNg. We demonstrated that IFNg inhibited NF-kB activation induced by TNFa without suppressing its DNA-binding activity. Similarly, it was recently reported that IFNg sensitized ME 180 cells to TNFa-Àinduced apoptosis by inhibiting NF-kB activation (Suk et al., 2001a) . In accordance with our results, they found that IFNg did not affect TNFainduced DNA binding of NF-kB while it inhibited NFkB-mediated transactivation. Induction of the Stat1/ IRF1 pathway was important for this IFNg-mediated inhibition of NF-kB activity since ectopic expression of IRF1 was able to inhibit TNFa-mediated NF-kB activation. The inhibitory effect of IRF1was abrogated by the overexpression of the coactivator p300, suggesting a possible competition between the transcription factors for a scanty amount of common transcriptional coactivator(s) (Suk et al., 2001a) . In contrast, although IFNg/IFNa treatment triggered a synergistic apoptosis in SK-N-MC cells, we did not observe any effect of these cytokines on NF-kB activity. Thus, the synergistic effect of these two cytokines is independent of the NF-kB pathway. Whether additional mechanism to IRF1 induction and TRAIL production are implicated remains to be determined.
Although further investigations need to be done, particularly in animal models, the observations reported here might contribute to the development of alternative new approaches to the treatment of Ewing tumors resistant to conventional therapy.
Materials and methods

Cell lines, reagents and cytokines
The Ewing sarcoma SK-N-MC cell line (HTB10) and the Jurkat cell line were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). NB4 cells were a gift from Dr M. Lanotte (Hopital St Louis, Paris, France). Cells were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum Myoclone plus, 1% gentamycin and 2 mM L-glutamine and incubated at 371C in a humidified atmosphere of 5% CO 2 . Stimulations were performed in 2% FCS RPMI to limit the effect of the serum constituents. Recombinant human IFNa2b (specific activity: 1 Â 10 8 U/mg) was a gift from BioSidus (Buenos Aires, Argentina). Recombinant human IFNg (specific activity 2 Â 10 7 U/mg) was a gift from Roussel Uclaf, France. Recombinant human TNFa (specific activity 5 Â 10 7 U/mg), was a gift from Boehringer/Ingelheim (Vienna, Austria). Recombinant human TRAIL (375 TEC) was purchased from R&D systems Europe Ltd.
Cell death assays
Cytotoxicity assay Cells (10 5 in 500 ml) were seeded in 24-well plates, allowed to attach overnight and stimulated with the IFNs (1000 U/ml), with TNFa (1000 U/ml) or with TRAIL at the indicated concentrations. After 24 h, WST1 dye reagent (Roche Molecular Biochemicals, Mannheim, Germany) was added (I/10 vol.) and the plates were incubated at 371C (Liu et al., 1995) . The absorbance was read at 450 nM with a cytofluorometer Victor 2 (Perkin-Elmer Life Sciences Inc., Boston, MA, USA) after 4 h of incubation. Results are expressed as percentage of dead cells in the population of treated cells as compared to controls with the formula %dead ¼ 1 À ðDO sample À backgroundÞ ðDO control À backgroundÞ Â100:
Apo2-7 labeling Cells (10 6 /ml) were stimulated in six-well plates, as described in the figure legends. Cells were then recovered, washed with PBS and plated again in 96-well plates at the density of 3 Â 10 5 cells per well. They were incubated for 30 min in the dark at room temperature with the PEconjugated antibody Apo2-7 (Immunotech Coulter company, Marseille, France), an antibody that recognizes a mitochondrial protein that is expressed in the early stages on cells undergoing apoptosis. PE-conjugated mouse IgG1 was used as a control (Zhang et al., 1996) . The cells were then washed with PBS and fixed in 1% formaldehyde before analysis with a FACScan (Becton Dickinson, Heidelberg, Germany). The results, analysed using the Lysis II software, are expressed in fold increase of the Mean Fluorescence Intensity.
Fragmented nuclei were detected by staining with Hoechst 33258 fluorescent dye (Dapi). A total of 300 nuclei were counted for each sample.
DNA fragmentation was quantified using a cell death detection kit ELISA (Roche Diagnostics), according to the manufacturer's instructions. This method measures the fragmentation of DNA by a quantitative immunoassay using mouse monoclonal antibody against DNA and histones, which allows the specific determination of mono-and oligonucleosomes in the cytoplasmic fraction of the apoptotic cell lysates.
Immunofluorescent staining and flow cytometry
Cells (10 6 /ml), were seeded in six-well plates, allowed to attach overnight and then stimulated by IFNg/IFNa or IFNg/TNFa combinations (1000 U/ml each) for 24 h. They were then resuspended, washed with PBS/1% BSA and plated in 96-well plates at the density of 3 Â 10 5 cells/well. Cells were permeabilized or not with digitonin (100 mg/ml) and incubated with 5 mg of monoclonal mouse anti-TRAIL (2E5 from Alexis Biochemicals) or goat anti-TRAIL-R2 (DR5) (AF631 from R&D Systems) antibodies for 30 min at 41C, followed by antimouse or anti-goat FITC antibodies Immunotech), respectively, for 30 min at 41C. After washing, the cells were fixed in 1% formaldehyde and analysed in a FACScan. Results were analysed with the Lysis II software and are expressed in % of specifically labeled cells.
RT-PCR
Cells were treated with IFNa, IFNg, TNFa, IFNg/IFNa and IFNg/TNFa (1000 U/ml), for the indicated times, and total RNA was prepared by the guanidium/thiocyanate method. For the reverse transcription reaction, 1 mg of total RNA was annealed in 67 mM MgCl 2 buffer with 100 pmol of random hexamer (Boehringer) and 25 mM of dNTPs (Amersham Pharmacia Biotech, Orsay, France) for 5 min at 651C and then subjected to reverse transcription with 2 U of reverse transcriptase (M MLV from Invitrogen) and 1 U of human placenta ribonuclease inhibitor (Amersham) for 30 min at 421C. cDNA were submitted to PCR with specific primers for TRAIL (forward 5 0 -CAACTCCGTCAGCTCGTTAGAA AG-3 0 ; reverse 5 0 -TTAGACCAACAACTATTTCTAGCA CT-3 0 ) that generate a 443 bp fragment. The reaction was done in a 17 mM MgCl 2 buffer, in the presence of 25 mM of dNTPs and 2.5 U of Taq polymerase (Roche), with a program of 30 cycles of 45 s at 951C, 45 s at 551C and 45 s at 721C ). An internal standard EWS/FLI1 transcript of 495 bp (Delattre et al., 1992) was used to normalize PCR products that were resolved on a 2% agarose gel and visualized in the presence of ethidium bromide using a densitometric video camera (Imager, Appligene, Illkirch, France).
Western blot analysis
The stimulated cells were lysed in 20 mM Tris, 1% Triton, 1% SDS for 30 min at 41C. The lysates were treated with benzon nuclease for 5 min at room temperature and cleared by centrifugation for 10 min at 9000 r.p.m. Protein content was determined with the protein assay dye reagent from Biorad. Cell lysates were mixed with Laemmli buffer, heated for 5 min at 951C and fractionated on 8 or 12% acrylamide gels and transferred onto a 0.22 mm nitrocellulose membrane (Schleicher and Schull, Dasel, Germany) . Nonspecific protein sites were blocked in 10 mM Tris, pH 8, 1 mM EDTA, 150 mM NaCl buffer with 5% nonfat dry milk for 2 h. The membranes were then incubated with dilutions of the antibodies in the same buffer for 2 h at room temperature followed by the secondary peroxidase-conjugated antibodies (anti-mouse or anti-rabbit immunoglobulins from Dako). Proteins were visualized by the chemiluminescence reagent plus (Perkin-Elmer). The antibodies used for membrane blotting were: polyclonal anti-TRAIL (AF375), anti-IRF1 and anti-Stat1(p91) antibodies from R&D, monoclonal anti-pS727 Stat1 and anti-pY701 Stat 1 antibodies from Santa Cruz Biotechnology, Inc. (Tebu, France), monoclonal anti-caspase-7 antibody from Transduction Laboratories (Lexington, KY, USA). The blots were also incubated with an anti-actin antibody (ICN Biomedicals, Orsay, France) to confirm the equal loading of the lanes.
Quantification of trail
Trail amounts were determined in both stimulated cell lysates and supernatants using two enzyme-linked immunoabsorbant assays (ELISA) from Active Motif Europe (Rixensart, Belgium) and from R&D. After treatment of cells with the different cytokines, supernatants were collected and the cells were lysed according to the manufacturer's instructions. A standard curve of 0.015-2 ng/ml of recombinant TRAIL was used as reference. All samples were assayed in duplicate and the plates were read in a cytofluorometer Victor 2 (PerkinElmer). Results are expressed as ng of TRAIL either secreted by 10 6 cells or associated with 10 6 cells.
Preparation of inducer-free supernatants
Cells were stimulated for 6 h, washed extensively to eliminate the stimuli and incubated in fresh medium for 2 days. The cytotoxicity of these 'inducer-free' supernatants was titrated by serial dilutions on naive SK-N-MC cells with the WST1 reagent. In parallel, each dilution of supernatant was incubated with 10 mg/ml of TRAIL-R2/Fc chimera (631 T2 from R&D) for 1 h at room temperature and then assayed for cytoxicity in parallel to the untreated dilutions.
NF-kB activity
Cells (10 7 ) were washed twice with serum-free medium and incubated for 10 min at 41C with 10 mg of (Igk)3-conaluc luciferase reporter plasmid (gift from A. ISRAEL) together with 2 mg of pCMV-b gal plasmid in OptiMEM medium (Invitrogen). Cells were then electroporated at 960 mF and 210 V, resuspended in 10% FCS RPMI and allowed to readhere overnight before stimulation for 8 h with TNFa and IFNg/TNFa. Reporter gene activity was determined with the luciferase assay system (Promega, Madison, WI, USA). Transfection efficiencies were normalized on the basis of b-galactosidase expression. b-galactosidase activity was measured by the luminescent Galacto-Star system (Tropix, Bedford, MA, USA).
The DNA-binding activity of NF-kB was measured in whole cell extracts (10 mg of proteins) using the Trans-AM p65 NFkB transcription factor assay kit (Active Motif) according to the manufacturer's protocol (Renard et al., 2001) .
